AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT01857622
Drug: DU-176b 60mg
RxNorm normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: oral DU-176b 60mg once daily
Trial: NCT00601003
Drug: Nifurtimox
RxNorm normalized name: nifurtimox
DrugBank: Nifurtimox (DB11820)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 30mg/kg/day PO divided into TID dosing q day
Trial: NCT00601003
Drug: Topotecan
RxNorm normalized name: Topotecan
DrugBank: Topotecan (DB01030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.75mg/m2/dose, in normal saline, IV, infused over 30 minutes on days 1-5 of each cycle.
Trial: NCT01654081
Drug: Irinotecan
RxNorm normalized name: Irinotecan
DrugBank: Irinotecan (DB00762)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Irinotecan 125 mg/m2 on days 1, 8, 15 and 22 of every 6- week cycle
Trial: NCT01589562
Drug: Megace 800mg/20ml
RxNorm normalized name: megestrol acetate Oral Tablet [Megace]
DrugBank: Megestrol acetate (DB00351)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Megestrol acetate 800mg/20ml, Suspension, Single dose
Trial: NCT03030937
Drug: Apatinib
RxNorm normalized name: Apatinib
DrugBank: Rivoceranib (DB14765)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apatinib, a novel targeted inhibitor of VEGF receptor 2 (VEGFR2).
Trial: NCT03030937
Drug: Irinotecan
RxNorm normalized name: Irinotecan
DrugBank: Irinotecan (DB00762)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Irinotecan was used as second line treatment with AGC.
Trial: NCT02641457
Drug: Aflibercept
RxNorm normalized name: Aflibercept
DrugBank: Aflibercept (DB08885)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 12 eyes received an intraocular injection of 2.00 mg of aflibercept (IA) and IOP were measured by tonometer. The neovascularization was evaluated by biomicroscope.
Trial: NCT02641457
Drug: Ranibizumab
RxNorm normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 12 eyes received an intraocular injection of 1.25mg ranibizumab and IOP were measured by tonometer. The neovascularization was evaluated by biomicroscope.
Trial: NCT01022801
Drug: Entecavir
RxNorm normalized name: Entecavir
DrugBank: Entecavir (DB00442)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Capsule, P.O., 0.01, 0.1 or 0.5 mg, once daily for 24 weeks
Trial: NCT03340558
Drug: Cobimetinib
RxNorm normalized name: Cobimetinib
DrugBank: Cobimetinib (DB05239)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: MEK inhibitor
Trial: NCT03061604
Drug: Octreotide
RxNorm normalized name: Octreotide
DrugBank: Octreotide (DB00104)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Octreotide will be administered to all patients at time of admission and will be continued for 24 hours~• Dosage: 50 mcg bolus at admission then 25 mcg/hour
Trial: NCT03061604
Drug: Ceftriaxone
RxNorm normalized name: Ceftriaxone
DrugBank: Ceftriaxone (DB01212)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ceftriaxone will be administered to all patients on daily basis
Trial: NCT00320814
Drug: VEGF Trap-Eye
RxNorm normalized name: Trapa bicornis seed extract
DrugBank: Corn (DB10572)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single IVT injection of 4.0 mg of VEGF Trap-Eye into the study eye on Day 1
Trial: NCT04573556
Drug: Lemborexant
RxNorm normalized name: Lemborexant
DrugBank: Lemborexant (DB11951)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Lemborexant oral tablets.
Trial: NCT02724293
Drug: pregabaline 300 mg once.
DrugBank: Pregabalin (DB00230)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: patients received pregabaline 300 mg 2 hours pre-operatively.
Trial: NCT00977769
Drug: carbetocin 100 µg
DrugBank: Carbetocin (DB01282)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hemodynamic effect of
Trial: NCT02724293
Drug: pregabaline 300 mg twice.
DrugBank: Pregabalin (DB00230)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: patients received pregabaline 300 mg 2 hours pre-operatively, and 12 hours later.
Trial: NCT00977769
Drug: oxytocin 5 u
RxNorm normalized name: oxytocin 5 UNT/ML
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hemodynamic effect of
Trial: NCT00628914
Drug: escitalopram and eszopiclone
RxNorm normalized name: Eszopiclone
DrugBank: Citalopram (DB00215)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: escitalopram 10mg tabs QD and eszopiclone 3 mg tabs QD for 8 weeks
Trial: NCT00628914
Drug: Escitalopram, eszopiclone, and placebo
DrugBank: Citalopram (DB00215)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Escitalopram 10mg tabs QD for 8 weeks; Eszopiclone 3mg tabs QD for initial 4 weeks then placebo tabs QD for final 4 weeks
Trial: NCT00628914
Drug: Escitalopram
RxNorm normalized name: Escitalopram
DrugBank: Escitalopram (DB01175)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Escitalopram 10mg tabs QD and placebo tabs QD for 8 weeks
Trial: NCT01215214
Drug: midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: midazolam: 3mg iv
Trial: NCT02724293
Drug: pregabaline 600 mg once.
DrugBank: Pregabalin (DB00230)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: patients received pregabaline 600 mg 2 hours pre-operatively.
Trial: NCT01257399
Drug: Mesalazine
RxNorm normalized name: mesalazine
DrugBank: Mesalazine (DB00244)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 400mg tablets
Trial: NCT00983905
Drug: Colchicine
RxNorm normalized name: Colchicine
DrugBank: Colchicine (DB01394)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: one 0.6 mg tablet twice daily at 7:45 am and 7:45 pm on Days 5 to 19
Trial: NCT00184197
Drug: Botulinum toxin
RxNorm normalized name: Botulinum toxin
DrugBank: Botulinum toxin type B (DB00042)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01114139
Drug: Ferumoxytol
RxNorm normalized name: Ferumoxytol
DrugBank: Ferumoxytol (DB06215)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: IV Ferumoxytol
Trial: NCT00280683
Drug: L-arginine
RxNorm normalized name: L-Arginine
DrugBank: L-arginine (DB17289)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: subjects will take matching 0.01 g/kg/day of L-arginine in divided doses for thre months.
Trial: NCT01169636
Drug: Panobinostat
RxNorm normalized name: Panobinostat
DrugBank: Panobinostat (DB06603)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Starting Day -6 of Cycle 1, 20 mg orally on Monday, Wednesday, and Friday during Cycles 1 and 2 (Days -6, -4, and -2 of Cycle 1 and Days 1, 3, 5, 8, 10, and 12 of Cycles 1 and 2); MTD found in Phase 1 used for same schedule in Phase 2.
Trial: NCT01169636
Drug: Ifosfamide
RxNorm normalized name: Ifosfamide
DrugBank: Ifosfamide (DB01181)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Day 1 of Cycles 1-3, 5 grams/m2 by vein over 24 hours.
Trial: NCT01169636
Drug: Mesna
RxNorm normalized name: Mesna
DrugBank: Coenzyme M (DB09110)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: On Day 1 of Cycles 1-3, 2 grams/m2 by vein over 12 hours.
Trial: NCT01169636
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: On Day 1 of Cycles 1-3, Standard Dose (Target area under curve (AUC) = 5mg/ml/min) by vein over 1 hour.
Trial: NCT01169636
Drug: Etoposide
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: On Days 1-3 of Cycles 1-3, 100 mg/m2 by vein over 2 hours.
Trial: NCT01169636
Drug: Pegfilgrastim
RxNorm normalized name: Pegfilgrastim
DrugBank: Pegfilgrastim (DB00019)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Beginning Day 4 of Cycles 1-3, 6 mg under the skin.
Trial: NCT02875834
Drug: Sodium Zirconium Cyclosilicate (ZS) 10g
DrugBank: Sodium zirconium cyclosilicate (DB14048)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Suspension administered 10g orally three times per day, in the first 48-hour of the study for all patients (48-hour open label initial phase)
Trial: NCT02875834
Drug: Sodium Zirconium Cyclosilicate (ZS) 5g
DrugBank: Sodium zirconium cyclosilicate (DB14048)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Suspension administered 5g orally once daily for 28 days after the first 48-hour open label initial phase.
Trial: NCT02875834
Drug: Sodium Zirconium Cyclosilicate (ZS) 10g
DrugBank: Sodium zirconium cyclosilicate (DB14048)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Suspension administered 10g orally once daily for 28 days after the first 48-hour open label initial phase.
Trial: NCT01951378
Drug: Albuterol
RxNorm normalized name: Albuterol
DrugBank: Albuterol (DB01001)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects may have started treatment prior to consent and may receives unit dose (2.5 mg) Albuterol/Proventil treatments will be given with a standard nebulizer up to 3 times as needed and may change over to study randomized device once consented to eith arm.
Trial: NCT02899702
Drug: PRIVIGEN (CSL Behring)
RxNorm normalized name: Privigen
DrugBank: Human immunoglobulin G (DB00028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single administration of intravenous immunoglobulin solution Privigen® (CSL Behring AG, Bern, Switzerland) at a dose of 2g / kg. IGIV 2g/kg within 12 hours following PICU admission (or outbreak of first shock signs).~The treatment of toxic shock will be standardized. It consists of antibiotics: Amoxicillin-clavulanate and clindamycin (or Rifampicin, Rifadine® if allergic). Antibiotics are not considered as experimental treatments for this study. All treatments essential for the treatment of acute condition will be allowed and are not considered as experimental treatments for this study.
Trial: NCT00489645
Drug: pramlintide
RxNorm normalized name: Pramlintide
DrugBank: Pramlintide (DB01278)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: pramlintide SC during eglycemia
Trial: NCT00489645
Drug: pramlintide
RxNorm normalized name: Pramlintide
DrugBank: Pramlintide (DB01278)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: pramlintide SC during hyperglycemia
Trial: NCT00863798
Drug: Desvenlafaxine Succinate Sustained-Release 10mg
DrugBank: Venlafaxine (DB00285)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 10 mg tablet, once daily dosing for 8 weeks
Trial: NCT02899702
Drug: Albumin
RxNorm normalized name: Albumin
DrugBank: Albumin human (DB00062)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4%(LFB) ALBUMIN Single administration of human Albumin 4% diluted albumin (VIALEBEX® LFB), within 12 hours following PICU admission (or outbreak of first shock signs). Isovolume - so dose of 0.8 g/kg (4gG, 100 ML, Sodium chloride 0.61 G / 100ML Water for injections QSP 100 ML Sodium caprylate 0.3 G / 100ML) We chose as placebo albumin diluted to 4% because this solution has the advantage of having a comparable osmolality.~The treatment of toxic shock will be standardized. It consists of antibiotics: Amoxicillin-clavulanate and clindamycin (or Rifampicin, Rifadine® if allergic). Antibiotics are not considered as experimental treatments for this study. All treatments essential for the treatment of acute condition will be allowed and are not considered as experimental treatments for this study.
Trial: NCT01812265
Drug: PF-06305591
RxNorm normalized name: PF-06305591
DrugBank: PF-06305591 (DB12106)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single Dose
Trial: NCT00815594
Drug: bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 0.05ml, 1.25mg
Trial: NCT00503321
Drug: Tegafur/gimeracil/oteracil potassium (S-1), Krestin (PSK)
DrugBank: Oteracil (DB03209)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: S-1 80mg/m2 4weeks on 2 weeks off, PSK 3g/day
Trial: NCT00503321
Drug: Tegafur/gimeracil/oteracil potassium (S-1)
DrugBank: Oteracil (DB03209)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: S-1 80mg/m2, 4weeks on followed by 2 weks off
Trial: NCT00863798
Drug: Desvenlafaxine Succinate Sustained-Release 50 mg
RxNorm normalized name: desvenlafaxine succinate 50 MG
DrugBank: Venlafaxine (DB00285)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 50 mg tablet, once daily dosing for 8 weeks
Trial: NCT02057003
Drug: DAA against HCV
RxNorm normalized name: HCV-086
DrugBank: HCV-086 (DB05884)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02866071
Drug: Ketamine Hydrochloride
RxNorm normalized name: Ketamine Hydrochloride
DrugBank: Ketamine (DB01221)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 50mg IN Ketamine Hydrochloride
Trial: NCT04296422
Drug: NSAIDs or oral contraceptives treatment
RxNorm normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Taking NSAIDs or oral contraceptives.NSAIDs include Ibuprofen, Naproxen, Diclofenac, and Piroxicam. Oral contraceptives include Yasmin.
Trial: NCT05505253
Drug: Alfacalcidol 0.0005 MG
RxNorm normalized name: alfacalcidol 0.0005 MG
DrugBank: Alfacalcidol (DB01436)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alfacalcidol 0.5 mcg is given orally for 3 months, then vitamin D3 and vitamin D receptor levels are measured
Trial: NCT03545373
Drug: Amoxicillin
RxNorm normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amoxicillin tablets taken orally
Trial: NCT02961374
Drug: Erlotinib
RxNorm normalized name: Erlotinib
DrugBank: Erlotinib (DB00530)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT02961374
Drug: Erlotinib Hydrochloride
RxNorm normalized name: Erlotinib Hydrochloride
DrugBank: Erlotinib (DB00530)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT01620307
Drug: Sirolimus (Rapamune 2mg/day, Pfizer)
RxNorm normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Sirolimus (Rapamune 2mg/day, Pfizer) or not for a course of 14 days.
Trial: NCT03386955
Drug: BPI-7711 Capsule
RxNorm normalized name: BPI-3016
DrugBank: BPI-3016 (DB15158)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phase I: BPI-7711 capsule(30mg, 60mg, 120mg, 180mg, 240mg...) Phase IIa: BPI-7711 capsule(with recommend phase II dose)
Trial: NCT02637856
Drug: Ocrelizumab
RxNorm normalized name: Ocrelizumab
DrugBank: Ocrelizumab (DB11988)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Participants will receive ocrelizumab as an initial dose of two 300-mg IV infusions (600 mg total) separated by 14 days (on Days 1 and 15) followed by one 600-mg IV infusion every 24 weeks for a maximum of 4 doses (up to 96 weeks).
Trial: NCT02637856
Drug: Ocrelizumab
RxNorm normalized name: Ocrelizumab
DrugBank: Ocrelizumab (DB11988)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Participants will receive an additional single 600-mg dose IV infusion at a shorter infusion rate (approximately 2 hours instead of 3.5 hours)
Trial: NCT00784147
Drug: Ibalizumab
RxNorm normalized name: ibalizumab
DrugBank: Ibalizumab (DB12698)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Ibalizumab 800 mg IV every 2 weeks
Trial: NCT00784147
Drug: Ibalizumab
RxNorm normalized name: ibalizumab
DrugBank: Ibalizumab (DB12698)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Ibalizumab 2000 mg IV every 4 weeks
Trial: NCT00440388
Drug: AT-101
RxNorm normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AT-101 30 mg orally for 21 of 56 days, every cycle. Cycle = 56 days; Max of 5 cycles.
Trial: NCT00440388
Drug: Rituximab
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Rituximab 375mg/m2 IV once per week for four weeks during 1st cycle, 375mg/m2 IV once per cycle for cycles 2-5. Cycle = 56 days; Max of 5 cycles.
Trial: NCT00319059
Drug: systemic administration of 99mTc-HYNIC-Annexin A5
RxNorm normalized name: Oil of peppermint
DrugBank: Peppermint oil (DB11198)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01649557
Drug: OPC-34712
RxNorm normalized name: OPC-14523
DrugBank: OPC-14523 (DB05422)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral administered once daily
Trial: NCT03932578
Drug: Atropine sulfate
RxNorm normalized name: Atropine Sulfate
DrugBank: Atropine (DB00572)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients will receive intrathecal 100 μg of a 1 mg/ml preservative-free atropine sulfate solution
Trial: NCT03932578
Drug: Metoclopramide
RxNorm normalized name: Metoclopramide
DrugBank: Metoclopramide (DB01233)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients will receive IV metoclopramide 10 mg in 2 ml
Trial: NCT02019875
Drug: Rifampin
RxNorm normalized name: Rifampin
DrugBank: Rifampin (DB01045)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: P450 inducer
Trial: NCT00004275
Drug: growth hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00004275
Drug: oxandrolone
RxNorm normalized name: Oxandrolone
DrugBank: Oxandrolone (DB00621)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00147303
Drug: MCI-9042
RxNorm normalized name: samarium Sm153 50 MCI/ML [Quadramet]
DrugBank: Samarium (DB12403)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00048776
Drug: Pletal
RxNorm normalized name: Pletal
DrugBank: Cilostazol (DB01166)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00591123
Drug: 5-FU
RxNorm normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 5-FU 2400 mg/m2 IV will be given via pump for 46-48 hours at home.
Trial: NCT04485299
Drug: Sodium Fluoride 5% Dental Varnish
RxNorm normalized name: SODIUM FLUORIDE 5% DENTAL VARNISH
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 5% NaF
Trial: NCT00384098
Drug: CTA018 cream
RxNorm normalized name: CTA018
DrugBank: CTA018 (DB05024)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00591123
Drug: Erlotinib
RxNorm normalized name: Erlotinib
DrugBank: Erlotinib (DB00530)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All patients will also be given Erlotinib, 100 mg orally daily for the first 4 weeks. Those patients who have not experienced toxicities will increase the dose level to 150 mg daily. Patients who have toxicities will remain at the 100 mg dose level or lower if necessary.
Trial: NCT03481556
Drug: Melphalan flufenamide (Melflufen)
DrugBank: Melphalan flufenamide (DB16627)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous infusion
Trial: NCT03481556
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral tablets
Trial: NCT03481556
Drug: Bortezomib
RxNorm normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Subcutaneous administration
Trial: NCT03481556
Drug: Daratumumab
RxNorm normalized name: Daratumumab
DrugBank: Daratumumab (DB09331)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intravenous infusion
Trial: NCT00495872
Drug: Dasatinib
RxNorm normalized name: Dasatinib
DrugBank: Dasatinib (DB01254)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 50 mg by mouth (PO) Twice Daily for 28 Days Every 28 Days
Trial: NCT00495872
Drug: Erlotinib
RxNorm normalized name: Erlotinib
DrugBank: Erlotinib (DB00530)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 100 mg PO Daily for 28 Days Every 28 Days
Trial: NCT00495872
Drug: Lapatinib
RxNorm normalized name: Lapatinib
DrugBank: Lapatinib (DB01259)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 1000 mg PO Daily for 28 Days Every 28 Days
Trial: NCT00495872
Drug: Lenalidomide
RxNorm normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 15 mg PO Daily for 28 Days Every 28 Days
Trial: NCT00495872
Drug: Sorafenib
RxNorm normalized name: Sorafenib
DrugBank: Sorafenib (DB00398)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 400 mg PO Daily for 21 Days Every 28 Days
Trial: NCT00495872
Drug: Sunitinib
RxNorm normalized name: Sunitinib
DrugBank: Sunitinib (DB01268)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 25 mg PO Daily for 21 Days Every 28 Days
Trial: NCT00495872
Drug: Valproic Acid
RxNorm normalized name: Valproic Acid
DrugBank: Valproic acid (DB00313)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 40 mg/kg PO Daily for 7 Days, then 7 Days Off
Trial: NCT02687490
Drug: Abraxane
RxNorm normalized name: Abraxane
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 125 mg/m2, D1, D8, D15
Trial: NCT01091896
Drug: Bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 1.25 mg of bevacizumab (0.05 ml) 7 days before vitrectomy
Trial: NCT01091896
Drug: bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 1.25 mg of bevacizumab (0.05 ml) at the end of vitrectomy
Trial: NCT00720369
Drug: CoEnzyme Q10
RxNorm normalized name: Coenzyme Q10
DrugBank: Ubidecarenone (DB09270)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: CoEnzyme Q10 with dosage range from 400 mg to 1200 mg per day
Trial: NCT02176564
Drug: inhaled bronchodilator
RxNorm normalized name: Bronchodil
DrugBank: Reproterol (DB12846)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01476813
Drug: Glycopyrrolate
RxNorm normalized name: Glycopyrrolate
DrugBank: Glycopyrronium (DB00986)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: comparison of different dosages of drug
Trial: NCT02541045
Drug: metadoxine
RxNorm normalized name: metadoxine
DrugBank: Metadoxine (DB16554)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: metadoxine 500mg tablets: 1 Tablet by mouth twice in day during 6 months
Trial: NCT00107978
Drug: Telavancin
RxNorm normalized name: Telavancin
DrugBank: Telavancin (DB06402)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Telavancin 10 mg/kg/day, IV for up to 14 days.
Trial: NCT00107978
Drug: Vancomycin
RxNorm normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vancomycin 1 Gm IV administered every 12 hrs for up to 14 days.